ValiRx Share Price (VAL)

1.15 -0.05 (-4.17%) delayed: 12:49PM GMT
Bid price 1.10 Open price 1.12
Ask price 1.20 Prev close 1.20
High price 1.21 Spread 8.33%
Low price 1.12 Volume 1,115,563

Register now for FREE live ValiRx share prices, ValiRx stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get ValiRx Level 2 Data, indepth research tools and investor commentary for ValiRx (VAL) and other London Stock Exchange equities.

ValiRx Share Price Chart

Advanced Charts >>

Register now for FREE ValiRx share price charts

ValiRx Share Price Information

Name ValiRx Epic VAL
Sector Pharmaceuticals & Biotechnology ISIN GB00BWWYSP41
Activites ValiRx Plc is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in precision medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention. The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. Index n/a

ValiRx Key Numbers

Latest Share Price (p) 1.15 Net Gearing (%) 21.94
Market Capitalisation (£m) 5.85 Gross Gearing (%) 36.14
Shares in issue (m) 531.63 Debt Ratio 0.00
P/E Ratio -0.58 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.57
Dividend Yield (%) 0.00 Price to book value 1.86
Dividend cover (x) 0.00 ROCE (%) -112.34
Earning per share (p) -1.90 EPS Growth (%) 77.75
52 week high / low 7.73 / 1.05 DPS Growth (%) n/a

ValiRx Director Deals

Dec.Date Type Director Pos No. of Shares
15/03/2017 BUY Satu Vainikka CEO 400,000
15/03/2017 BUY George Morris ED 400,000
15/03/2017 BUY Gerald Desler FD 400,000
02/03/2017 PLAC Satu Vainikka CEO 400,000
02/03/2017 PLAC George Morris ED 400,000

More ValiRx Director Deals >>

ValiRx Company News

09:03 10/12/2018

UK stocks open 0.3% lower as global trade tensions simmer

UK stocks opened lower on Monday as investors continued to fret about US-China trade tensions and Theresa May's Brexit deal looked destined for failure at a crucial Tuesday vote. At 0857, the benchmark FTSE 100 index was down 19.19 points, or 0.3%, at 6.758.92. Retirement income company Just...

08:14 10/12/2018

ValiRx welcomes positive trial results for prostate cancer treatment

ValiRx said an independent analysis of data showed a statistically significant response in a treatment trial involving patients with hormone-sensitive and hormone-resistant prostate cancer. The results came from an initial formal statistical analysis of clinical data for the treatment, VAL201,...

07:00 10/12/2018

Update on VAL201 Clinical Trial

RNS Number : 8910J ValiRx PLC 09 December 2018       VALIRX PLC ("ValiRx" or the "Company")   UPDATE ON VAL201 CLINICAL TRIAL "Positive Effect on Cancer Patients" "Evidence revealed of decrease in prostate cancer biomarker PSA, related to dosing with...

More ValiRx Company News >>

Register now for FREE ValiRx company news

ValiRx Share Price Discussions

10 months ago

ValiRx Plc - Bioscience Innovation (VAL)

Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that...

more than 1 year ago

(VAL)

Dr Satu Vainikka, CEO commented: "I am delighted that we are now launching our Chlamydia self-testing product into the UK and Irish markets. With Chlamydia being diagnosed as the fastest growing sexually transmitted disease at the moment, our self-testing pack, as an affordable, easy -to-use...

Register now for FREE ValiRx share price discussions